Emerging drugs of abuse: current perspectives on substituted cathinones

被引:82
作者
Paillet-Loilier, Magalie [1 ]
Cesbron, Alexandre [1 ]
Le Boisselier, Reynald [2 ]
Bourgine, Joanna [1 ]
Debruyne, Daniele [1 ,2 ]
机构
[1] Univ Hosp Ctr, Dept Pharmacol, Toxicol & Pharmacol Lab, Caen, France
[2] Univ Hosp Ctr, CEIP A, Dept Pharmacol, Caen, France
关键词
substituted cathinones; chemistry; analysis; pharmacology; toxicology; dependence; medical care;
D O I
10.2147/SAR.S37257
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Substituted cathinones are synthetic analogs of cathinone that can be considered as derivatives of phenethylamines with a beta-keto group on the side chain. They appeared in the recreational drug market in the mid-2000s and now represent a large class of new popular drugs of abuse. Initially considered as legal highs, their legal status is variable by country and is rapidly changing, with government institutions encouraging their control. Some cathinones (such as diethylpropion or pyrovalerone) have been used in a medical setting and bupropion is actually indicated for smoking cessation. Substituted cathinones are widely available from internet websites, retail shops, and street dealers. They can be sold under chemical, evocative or generic names, making their identification difficult. Fortunately, analytical methods have been developed in recent years to solve this problem. Available as powders, substituted cathinones are self-administered by snorting, oral injestion, or intravenous injection. They act as central nervous system stimulants by causing the release of catecholamines (dopamine, noradrenaline, and serotonin) and blocking their reuptake in the central and peripheral nervous system. They may also decrease dopamine and serotonin transporter function as nonselective substrates or potent blockers and may inhibit monoamine oxidase effects. Nevertheless, considerable differences have been found in the potencies of the different substituted cathinones in vitro. Desired effects reported by users include increased energy, empathy, and improved libido. Cardiovascular (tachycardia, hypertension) and psychiatric/neurological signs/symptoms (agitation, seizures, paranoia, and hallucinations) are the most common adverse effects reported. Severe toxicity signs compatible with excessive serotonin activity, such as hyperthermia, metabolic acidosis, and prolonged rhabdomyolysis, have also been observed. Reinforcing potential observed in animals predicts a high potential for addiction and abuse in users. In case of overdose, no specific antidote exists and no curative treatment has been approved by health authorities. Therefore, management of acute toxic effects is mainly extrapolated from experience with cocaine/amphetamines.
引用
收藏
页码:37 / 52
页数:16
相关论文
共 105 条
[71]   Suspected and Confirmed Fatalities Associated With Mephedrone (4-Methylmethcathinone, "Meow Meow'') in the United Kingdom [J].
Schifano, Fabrizio ;
Corkery, John ;
Ghodse, A. Hamid .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (05) :710-714
[72]   Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat [J].
Shortall, Sinead E. ;
Macerola, Alice E. ;
Swaby, Rabbi T. R. ;
Jayson, Rebecca ;
Korsah, Chantal ;
Pillidge, Katharine E. ;
Wigmore, Peter M. ;
Ebling, Francis J. P. ;
Green, A. Richard ;
Fone, Kevin C. F. ;
King, Madeleine V. .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 (09) :1085-1095
[73]   Manganese-induced parkinsonism in methcathinone abusers: bio-markers of exposure and follow-up [J].
Sikk, K. ;
Haldre, S. ;
Aquilonius, S. -M. ;
Asser, A. ;
Paris, M. ;
Roose, A. ;
Petterson, J. ;
Eriksson, S. -L. ;
Bergquist, J. ;
Taba, P. .
EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (06) :915-920
[74]   Pharmacological characterization of designer cathinones in vitro [J].
Simmler, L. D. ;
Buser, T. A. ;
Donzelli, M. ;
Schramm, Y. ;
Dieu, L-H ;
Huwyler, J. ;
Chaboz, S. ;
Hoener, M. C. ;
Liechti, M. E. .
BRITISH JOURNAL OF PHARMACOLOGY, 2013, 168 (02) :458-470
[75]   Methylone and Monoamine Transporters: Correlation with Toxicity [J].
Sogawa, Chiharu ;
Sogawa, Norio ;
Ohyama, Kazumi ;
Kikura-Hanajiri, Ruri ;
Goda, Yukihiro ;
Sora, Ichiro ;
Kitayama, Shigeo .
CURRENT NEUROPHARMACOLOGY, 2011, 9 (01) :58-62
[76]   Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid-chromatography-electrospray tandem mass spectrometry [J].
Sorensen, Lambert K. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2011, 879 (11-12) :727-736
[77]   Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States [J].
Spiller, Henry A. ;
Ryan, Mark L. ;
Weston, Robert G. ;
Jansen, Joanne .
CLINICAL TOXICOLOGY, 2011, 49 (06) :499-505
[78]   Metabolism of the new designer drug α-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′-methyl-α-pyffolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry [J].
Springer, D ;
Fritschi, G ;
Maurer, HH .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 796 (02) :253-266
[79]   Metabolism and toxicological detection of the new designer drug 4′-methoxy-α-pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry [J].
Springer, D ;
Fritschi, G ;
Maurer, HH .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 793 (02) :331-342
[80]   Metabolism of designer drugs of abuse [J].
Staack, RF ;
Maurer, HH .
CURRENT DRUG METABOLISM, 2005, 6 (03) :259-274